Prediction market traders estimate a 59% chance that OpenAI's upcoming AI model Astra, internally known as GPT-6, will launch by September 15, and about 72% by the end of September on Polymarket. This optimism contrasts with OpenAI's earlier announcement on August 7, where it stated that the release of Astra had been slowed due to cybersecurity risks. Internal evaluations indicated significant advancements in coding and cybersecurity, leading to concerns about critical cyber capabilities under its safety framework. The Polymarket odds suggest a near-term release, with the September 15 contract at 59% and a volume of 27600, while the September 30 contract shows 72% with a volume of 35600. A separate market indicates a 39% chance for a release between August 31 and September 6. On Myriad, another prediction market, traders assign 31% odds for a release by the end of September, with only 19% for September 15 and a mere 5% for August 21. The disparity between OpenAI's cautious approach and trader optimism is common, as prediction markets have seen significant activity, reaching 2 billion in weekly volume this year. OpenAI clarified that Astra was not involved in a recent incident with Hugging Face, as it continues to assess the model's safety.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.














Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.